Investigational drug · Phase 2
SV001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis(IPF).
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SV001"
First trial start
2025
Nov 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SV001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis(IPF)
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "SV001" as an intervention, largest first.
Shanghai Synvida Biotechnology Co.,Ltd.Industry
NCT06267183 · 53 participants (planned) · Start Jan 12, 2024 · Primary completion Nov 30, 2026
Drug: SV001; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Shanghai, China
Shanghai Synvida Biotechnology Co.,Ltd.Industry
NCT07121413 · 48 participants (planned) · Start Nov 4, 2025 · Primary completion Dec 31, 2026
Drug: SV001; Placebo · For: Idiopathic Pulmonary Fibrosis(IPF)
Sites: Chengdu, China; Guangzhou, China; Hangzhou, China · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Prebiotic Potential and Value-Added Products Derived from Spirulina laxissima SV001-A Step towards Healthy Living.
Sankarapandian V, Nitharsan K, Parangusadoss K, et al. · BioTech (Basel) 2022
- First Report of Rhizoctonia solani Causing a Disease of Sunflower in India.
Srinivasan K, Visalakchi S · Plant Dis 2010
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.